Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients

BACKGROUND: Skin cancers are known for their strong immunogenicity, which may contribute to a high treatment efficacy of immune checkpoint inhibition (ICI). However, a considerable proportion of patients with skin cancer is immuno-compromised by concomitant diseases. Due to their previous exclusion...

Descripción completa

Detalles Bibliográficos
Autores principales: Leiter, Ulrike, Loquai, Carmen, Reinhardt, Lydia, Rafei-Shamsabadi, David, Gutzmer, Ralf, Kaehler, Katharina, Heinzerling, Lucie, Hassel, Jessica C, Glutsch, Valerie, Sirokay, Judith, Schlecht, Nora, Rübben, Albert, Gambichler, Thilo, Schatton, Kerstin, Pfoehler, Claudia, Franklin, Cindy, Terheyden, Patrick, Haferkamp, Sebastian, Mohr, Peter, Bischof, Lena, Livingstone, Elisabeth, Zimmer, Lisa, Weichenthal, Michael, Schadendorf, Dirk, Meiwes, Andreas, Keim, Ulrike, Garbe, Claus, Becker, Jürgen Christian, Ugurel, Selma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583786/
https://www.ncbi.nlm.nih.gov/pubmed/33093156
http://dx.doi.org/10.1136/jitc-2020-000897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583786/
https://www.ncbi.nlm.nih.gov/pubmed/33093156
http://dx.doi.org/10.1136/jitc-2020-000897

Ejemplares similares